GSK's groundbreaking immunotherapy drug Dostarlimab (Jemperli) has demonstrated remarkable clinical efficacy in treating locally advanced rectal cancer, achieving its primary trial endpoint. The mid-stage study reveals a significant proportion of patients experienced complete disease remission lasting over twelve months following treatment. This advancement represents a pivotal moment in oncology, potentially offering hope to patients with treatment-resistant rectal tumors and expanding therapeutic options beyond traditional surgical interventions.

Summary auto-generated by AI from the original publisher's content. Editorial standards.